Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/106002809102500917 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Safety evaluation of tetravalent meningococcal conjugate vaccine in combination with the inactivated poliomyelitis vaccine and diphtheria-tetanus-acellular pertussis vaccine for infants].
Zhonghua Yu Fang Yi Xue Za Zhi
January 2025
Immunization Program Institute of Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.
To investigate the safety of the tetravalent meningococcal conjugate vaccine (MPCV-ACYW) in combination with the inactivated poliomyelitis (IPV) vaccine and diphtheria-tetanus-acellular pertussis (DTaP) vaccine for infants aged 3-5 months and provide real-world evidence for the immunization strategy of vaccine combination. From June to October 2023, a total of 600 3-month-old infants were selected and divided into three groups: control group, mono-vaccination group and combined vaccination group. They were simultaneously or individually vaccinated with MPCV-ACYW, IPV and DTaP vaccines at 3, 4, and 5 months of age, respectively.
View Article and Find Full Text PDFBreaking Barriers: Addressing Gender Disparities in Hip Resurfacing Surgery Access in the United States.
Arch Bone Jt Surg
January 2024
Orthopedic Research Center, Department of Orthopedic Surgery, Mashhad University of Medical sciences, Mashhad, Iran.
Second-generation large-diameter head hip resurfacing (HR) arthroplasty has gained popularity in terms of its potential for minimal wear and the preservation of proximal femoral bone stock. HR faces challenges, such as increased hip fracture rates and adverse reactions to metal detritus, despite the fact that over one million metal-on-metal (MoM) arthroplasties have been performed globally. FDA issued warnings in 2011 and 2016 regarding higher failure rates in women and categorized MoM implants as high-risk, influencing U.
View Article and Find Full Text PDFImmunotherapy combined with chemotherapy without locoregional radiotherapy in metastatic nasopharyngeal carcinoma: two case reports and a literature review.
Front Immunol
January 2025
Department of Otolaryngology, Changhai Hospital, Naval Medical University, Shanghai, China.
Background: There is no consensus regarding the optimal regimen for metastatic nasopharyngeal carcinoma (dmNPC). Locoregional intensity modulated radiotherapy (LRRT) following palliative chemotherapy (PCT) has been shown to prolong the overall survival (OS) and improve the progression-free survival (PFS) of patients with dmNPC, compared with PCT alone. However, patients with a high tumor burden do not benefit from additional LRRT, which inevitably results in toxicity.
View Article and Find Full Text PDFGLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks.
Front Clin Diabetes Healthc
January 2025
School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy.
Transcranial direct current stimulation for patients with walking difficulties caused by cerebral small vessel disease: a randomized controlled study.
Front Aging Neurosci
January 2025
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Introduction: Cerebral small vessel disease (CSVD) is a chronic systemic degenerative disease affecting small blood vessels in the brain, leading to cognitive impairments. Transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique that applies low electrical currents to the scalp, shows promise in treating cognitive and movement disorders. However, further clinical evaluation is required to assess the long-term effects of tDCS on neuroplasticity and gait in patients with CSVD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!